Figure 2 ). (C) CYP450 gene expression (n = 3) from in situ differentiated Curiochips compared to ex situ differentiation, both at day 21 of differentiation. DILI model evaluation of in situ Curiochips was quantified by ALT activity after (D) APAP and (E) FIAU treatments, over (n = 16 for each condition). Data are expressed as mean ± SEM; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001; n.s., not significant. " width="100%" height="100%">
Journal: Gastro Hep Advances
Article Title: A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids
doi: 10.1016/j.gastha.2024.08.004
Figure Lengend Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16). Multiple comparisons were made between sequential days of culture. The yellow dotted line represents the date of complete HLO differentiation (corresponds to day 0 in Figure 2 ). (C) CYP450 gene expression (n = 3) from in situ differentiated Curiochips compared to ex situ differentiation, both at day 21 of differentiation. DILI model evaluation of in situ Curiochips was quantified by ALT activity after (D) APAP and (E) FIAU treatments, over (n = 16 for each condition). Data are expressed as mean ± SEM; ∗ P < .05; ∗∗ P < .01; ∗∗∗ P < .001; ∗∗∗∗ P < .0001; n.s., not significant.
Article Snippet: In situ differentiation of HLOs on Curiochips. (A) Confocal fluorescence imaging of HLOs differentiated directly on Curiochips with cell-specific staining of hepatocytes (CEBPA) and hepatic stellate cells (vimentin). (B) Kinetic albumin secretion from in situ and ex situ differentiation of HLOs (n = 16).
Techniques: In Situ, Fluorescence, Imaging, Staining, Ex Situ, Gene Expression, Activity Assay